ライフサイエンスコーパス: Kaplan-Meier analysis

1 corneal thickness (CCT), and graft survival (Kaplan-Meier analysis).

2 dure or drug dose adjustment, evaluated in a Kaplan-Meier analysis).

3 y end point was to compare overall survival (Kaplan-Meier analysis).

4 he recurrence-free curve was estimated using Kaplan-Meier analysis.

5 d overall recurrence were evaluated by using Kaplan-Meier analysis.

6 d probability of rebound and resistance with Kaplan-Meier analysis.

7 splantation graft survival was assessed with Kaplan-Meier analysis.

8 oth univariate and multivariate analysis and Kaplan-Meier analysis.

9 A, NRP-1, FOXO 3a and MelCAM were studied by Kaplan-Meier analysis.

10 Device longevity was estimated using Kaplan-Meier analysis.

11 The patency was evaluated by Kaplan-Meier analysis.

12 th graft survival was also explored by using Kaplan-Meier analysis.

13 Survival was analyzed by Kaplan-Meier analysis.

14 al of bladder cancer patients as revealed by Kaplan-Meier analysis.

15 ation of reduced recurrence-free survival by Kaplan-Meier analysis.

16 999 copies/mL) for 6, 9, or 12 months, using Kaplan-Meier analysis.

17 tive risk (lambda) and cumulative risk using Kaplan-Meier analysis.

18 number of photographs taken was evaluated by Kaplan-Meier analysis.

19 om from revascularization was estimated with Kaplan-Meier analysis.

20 stable microsatellites P = .0415), based on Kaplan-Meier analysis.

21 rates divided by incidence, as estimated by Kaplan-Meier analysis.

22 tional hazards regression model analysis and Kaplan-Meier analysis.

23 rvival (PFS) and overall survival (OS) using Kaplan-Meier analysis.

24 ion-free survival and overall survival using Kaplan-Meier analysis.

25 Survival was assessed using Kaplan-Meier analysis.

26 ar cumulative percentage of MAE was 12.5% by Kaplan-Meier analysis.

27 cause-specific survival (CSS), P = 0.012] by Kaplan-Meier analysis.

28 al hazards modeling and were evaluated using Kaplan-Meier analysis.

29 tuarial overall survival was calculated with Kaplan-Meier analysis.

30 and bone metastasis statuses was compared by Kaplan-Meier analysis.

31 Long-term survival was evaluated by Kaplan-Meier analysis.

32 ree survival (LPFS) were calculated by using Kaplan-Meier analysis.

33 m the first TACE session was calculated with Kaplan-Meier analysis.

34 cumulative incidence of PD was calculated by Kaplan-Meier analysis.

35 tients was assessed using Cox regression and Kaplan-Meier analysis.

36 iagnoses were obtained and used to perform a Kaplan-Meier analysis.

37 dney transplants at the same center by using Kaplan-Meier analysis.

38 the synthetic lethal gene is evaluated using Kaplan-Meier analysis.

39 recurrence free survival were explored using Kaplan-Meier analysis.

40 dementia and parkinsonism was estimated with Kaplan-Meier analysis.

41 Fisher exact test, analysis of variance, and Kaplan-Meier analysis.

42 and bone metastasis statuses was compared by Kaplan-Meier analysis.

43 n rank-sum tests, the Fisher exact test, and Kaplan-Meier analysis.

44 us immunosuppressant use was estimated using Kaplan-Meier analysis.

45 which was significant in both chi-square and Kaplan-Meier analysis.

46 ative risk of treatment failure by day 28 by Kaplan-Meier analysis.

47 associated genetic variants were assessed by Kaplan-Meier analysis.

48 ression analysis (37.4%) or the results of a Kaplan-Meier analysis (10.5%).

49 e who did not have angiography, according to Kaplan-Meier analysis (281/3085 [12.8%] vs 480/4158 [16.

50 By Kaplan-Meier analysis, 5-year survival was 35.7% (95% co

51 By using a Kaplan-Meier analysis, a person's cumulative probability

52 median follow-up of 5.2 (3.6, 6.9) years on Kaplan-Meier analysis, a significant nonlinear associati

53 Kaplan-Meier analysis according to low, intermediate, an

54 We used a modified Kaplan-Meier analysis, accounting for the competing risk

55 In a Kaplan-Meier analysis, amyloid positive subjects with mi

56 overall survival discrimination, with use of Kaplan Meier analysis and a univariate Cox proportional

57 nt recipients 61 years of age or older using Kaplan- Meier analysis and Cox proportional hazard model

58 ters and survival time was assessed by using Kaplan-Meier analysis and a Cox proportional hazards mod

59 ed time to progression was assessed by using Kaplan-Meier analysis and a Cox regression model.

60 se Neuroimaging Initiative were evaluated by Kaplan-Meier analysis and analyses of variance and covar

61 sed mortality within 90 days of operation by Kaplan-Meier analysis and assessed the role of patient a

62 We analysed events by Kaplan-Meier analysis and compared groups with a Cox pro

63 (2009-2019), comparing survival outcomes by Kaplan-Meier analysis and comparing other measures of ou

64 ated the probability of recanalisation using Kaplan-Meier analysis and conducted multivariate analysi

65 We used Kaplan-Meier analysis and Cox proportional hazard models

66 s and survival outcomes were investigated by Kaplan-Meier analysis and Cox proportional hazard models

67 tality were analyzed by NYHA IV status using Kaplan-Meier analysis and Cox proportional hazard models

68 Kaplan-Meier analysis and Cox proportional hazards model

69 Recurrence and survival were analyzed using Kaplan-Meier analysis and Cox proportional hazards model

70 Survival was analyzed using Kaplan-Meier analysis and Cox proportional hazards regre

71 Kaplan-Meier analysis and Cox proportional hazards regre

72 Kaplan-Meier analysis and Cox proportional hazards regre

73 Survival analysis was conducted using Kaplan-Meier analysis and Cox regression analysis.

74 Kaplan-Meier analysis and Cox regression models were use

75 idence of clinical outcome was determined by Kaplan-Meier analysis and Cox regression was used to eva

76 Kaplan-Meier analysis and Cox regression were used to ev

77 Kaplan-Meier analysis and Cox regression were used to se

78 Survival analysis was performed with Kaplan-Meier analysis and Cox regression.

79 Kaplan-Meier analysis and global nonlinear regression re

80 Kaplan-Meier analysis and hazard ratios were calculated

81 ere complete success rates at 24 months with Kaplan-Meier analysis and incidence of adverse events.

82 urrence-free survival (BRFS) was assessed by Kaplan-Meier analysis and log rank test.

83 Median ages at LoA were compared by Kaplan-Meier analysis and log-rank test.

84 By Kaplan-Meier analysis and log-rank testing, progression-

85 Kaplan-Meier analysis and multivariable Cox proportional

86 Kaplan-Meier analysis and multivariable Cox proportional

87 Patient survival was determined using Kaplan-Meier analysis and predictors of mortality were i

88 Kaplan-Meier analysis and proportional hazard regression

89 t macular atrophy after nAMD was examined by Kaplan-Meier analysis and proportional hazards regressio

90 Survival was evaluated by using Kaplan-Meier analysis and was compared by using Cox prop

91 HCC incidence was determined by Kaplan-Meier analysis, and baseline factors associated w

92 Survival was evaluated using Kaplan-Meier analysis, and Cox proportional hazards mode

93 Bi- and multivariable logistic regression, Kaplan-Meier analysis, and Cox proportional hazards mode

94 e evaluated with competing risks regression, Kaplan-Meier analysis, and Cox proportional hazards regr

95 Disease risk was assessed with Kaplan-Meier analysis, and epidemiologic variables were

96 Survival of the fellow eye was estimated by Kaplan-Meier analysis, and log-rank test was used to com

97 t and cumulative incidence were evaluated by Kaplan-Meier analysis, and relative risks were estimated

98 Primary patency by Kaplan-Meier analysis at 12 months (360 days) was 86.3%.

99 In the Kaplan-Meier analysis at 24 weeks, the rate of death wit

100 success of second glaucoma drainage devices (Kaplan-Meier analysis) at 1 year, 2 years, and 3 years w

101 The Kaplan-Meier analysis based on our patients cohort and t

102 esion revascularization (TLR) estimated with Kaplan-Meier analysis, clinical and hemodynamic improvem

103 The Kaplan-Meier analysis confirmed this result, with a 2-y

104 In univariate Kaplan-Meier analysis, counts of total (p = 0.010), clas

105 respect to HNSCC staging were compared using Kaplan-Meier analysis, Cox proportional hazards regressi

106 and stage-based survival were compared using Kaplan-Meier analysis, Cox proportional-hazards regressi

107 Kaplan-Meier analysis demonstrated a 5-year OS of 81% in

108 Kaplan-Meier analysis demonstrated a cumulative mortalit

109 Kaplan-Meier analysis demonstrated a dose-dependent decr

110 Kaplan-Meier analysis demonstrated a lower risk for graf

111 Kaplan-Meier analysis demonstrated a significant associa

112 Kaplan-Meier analysis demonstrated an 88.5% freedom from

113 Kaplan-Meier analysis demonstrated an increased risk of

114 Kaplan-Meier analysis demonstrated an increased risk of

115 Kaplan-Meier analysis demonstrated complete success rate

116 Kaplan-Meier analysis demonstrated few vision losses dur

117 Kaplan-Meier analysis demonstrated significant differenc

118 Kaplan-Meier analysis demonstrated significantly greater

119 Kaplan-Meier analysis demonstrated that a PFR of <1.4 wa

120 Kaplan-Meier analysis demonstrated that a stem cell-like

121 Kaplan-Meier analysis demonstrated that ADT users 70 yea

122 Kaplan-Meier analysis demonstrated that patterns of alig

123 A Kaplan-Meier analysis demonstrated that the 1.6 mA-min d

124 Furthermore, the results obtained via Kaplan-Meier analysis demonstrated the potential of radi

125 points included 1-year survival, survival by Kaplan-Meier analysis, duration of ventilation, intensiv

126 A Kaplan-Meier analysis evaluated the probability and its

127 By Kaplan-Meier analysis, event-free survival was significa

128 We applied Kaplan-Meier analysis for survival curves and mortality

129 By unadjusted Kaplan-Meier analysis for the composite end point of dea

130 The Kaplan-Meier analysis for time to first patency loss was

131 Kaplan-Meier analysis found a 9.7-month difference in me

132 By Kaplan-Meier analysis, freedom from AAA rupture was 97.6

133 By Kaplan-Meier analysis, freedom from reintervention was 6

134 =0.0050) and lower likelihood of survival on Kaplan-Meier analysis (hazard ratio 5.9, 95% CI 1.9-18.4

135 By Kaplan-Meier analysis, HCC incidence was higher, but not

136 Successful trabeculectomies, determined by Kaplan-Meier analysis, in which patients have intraocula

137 ned from the training cohort, in addition to Kaplan-Meier analysis including the log-rank test.

138 Kaplan-Meier analysis, including all patients with any s

139 By Kaplan-Meier analysis, inclusion of currently unaffected

140 However, Kaplan-Meier analysis indicated a longer survival time i

141 Kaplan-Meier analysis indicated a shorter survival time

142 Kaplan-Meier analysis indicates that the current AJCC sy

143 In the Kaplan-Meier analysis, individuals within the lowest ter

144 Using Kaplan-Meier analysis, inducible ischemia and late gadol

145 as more likely in group 1 than in group 2 in Kaplan-Meier analysis (Log Rank P=0.04).

146 gher colorectal cancer-specific mortality in Kaplan-Meier analysis (log-rank test, P < 0.0001), univa

147 iac risk factors and CMR were significant in Kaplan-Meier analysis (log-rank test, p = 0.0006 and p <

148 icantly with poor survival prognosis using a Kaplan-Meier analysis (log-rank test, P=5 x 10(-4)), sug

149 lant-free survival was investigated by using Kaplan-Meier analysis, log-rank tests, and Cox regressio

150 Kaplan-Meier analysis, log-rank tests, Fine and Gray com

151 By Kaplan-Meier analysis, median freedom from conduit surge

152 In Kaplan-Meier analysis, MTA1dE4 overexpression in tumor,

153 ariate adjusted outcomes were assessed using Kaplan-Meier analysis, multivariate cox regression, mult

154 Kaplan-Meier analysis of 1582 eyes that underwent incisi

155 A Kaplan-Meier analysis of 45 patients revealed that highe

156 Kaplan-Meier analysis of all the 294 adenocarcinoma nodu

157 Kaplan-Meier analysis of beta6 expression in 488 colorec

158 Kaplan-Meier analysis of both types of tumors showed tha

159 Kaplan-Meier analysis of data from 3455 patients with br

160 ere randomized into eight treatment arms for Kaplan-Meier analysis of defined survival end-point (3.0

161 Kaplan-Meier analysis of DFS and OS was performed and in

162 Kaplan-Meier analysis of disease-free survival and overa

163 Kaplan-Meier analysis of graft and patient survival and

164 Kaplan-Meier analysis of graft and patient survival foun

165 The aggregated Kaplan-Meier analysis of immunotherapy trials vs chemoth

166 Kaplan-Meier analysis of metastasis-free survival and ov

167 Kaplan-Meier analysis of node-negative and node-positive

168 Kaplan-Meier analysis of our population indicated a 1-y

169 Kaplan-Meier analysis of overall survival (OS), progress

170 Descriptive statistics and Kaplan-Meier analysis of overall survival are reported.

171 Kaplan-Meier analysis of PET/CT-based staging showed pro

172 Kaplan-Meier analysis of rates of radiation complication

173 A Kaplan-Meier analysis of recurrence-free survival showed

174 FINDINGS: Kaplan-Meier analysis of the Kaiser validation cohort sh

175 up vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P = .7

176 By Kaplan-Meier analysis, OS, PFS, and LPFS were lower in p

177 In Kaplan-Meier analysis over a 5-year follow-up period, su

178 By Kaplan-Meier analysis, overall survival was significantl

179 C index = 0.724, p < 0.001) and mortality in Kaplan-Meier analysis (p < 0.001).

180 ssociated with survival from presentation in Kaplan-Meier analysis (p < 0.01), and loss of 1p36 and 1

181 higher incidence of cardiovascular events by Kaplan-Meier analysis (p = 0.033, log-rank test).

182 eved a 49% increase in tumor growth delay by Kaplan-Meier analysis (P = 0.0367; n = 6).

183 antly lower overall mortality, determined by Kaplan-Meier analysis (P=.0047), univariate Cox regressi

184 By Kaplan-Meier analysis, patients whose pancreatic cancer

185 In Kaplan-Meier analysis, patients whose tumours were CCS L

186 On Kaplan-Meier analysis, patients with dysfunction grade I

187 At Kaplan-Meier analysis, patients with LV involvement (LV

188 By Kaplan-Meier analysis, patients with MOLLI-ECV >/= the m

189 Kaplan-Meier analysis results showed that PAK after eith

190 Survival (Kaplan-Meier) analysis results suggest that the expressi

191 Kaplan Meier analysis revealed that 5-year and 10-year p

192 Kaplan-Meier analysis revealed a comparable survival pro

193 Kaplan-Meier analysis revealed a stepwise increase in mo

194 Kaplan-Meier analysis revealed a tendency of AR patients

195 Kaplan-Meier analysis revealed event-free survival for s

196 Kaplan-Meier analysis revealed no significant difference

197 Kaplan-Meier analysis revealed significant mortality bet

198 Kaplan-Meier analysis revealed similarly low cardiac eve

199 Kaplan-Meier analysis revealed that 5- and 10-year patie

200 Interestingly, Kaplan-Meier analysis revealed that a combined promoter

201 nipulation and no AI at the time of implant, Kaplan-Meier analysis revealed that freedom from greater

202 Kaplan-Meier analysis revealed that mortality and cardio

203 Kaplan-Meier analysis revealed that patients on hemodial

204 Kaplan-Meier analysis revealed that performance of AVR (

205 Kaplan-Meier analysis revealed that survival through day

206 A Kaplan-Meier analysis revealed that the rates of primary

207 The Kaplan-Meier analysis revealed the contraceptive vaginal

208 Kaplan-Meier analysis revealed the tendency of sleep apn

209 In Kaplan-Meier analysis, serum phosphate concentration was

210 Kaplan-Meier analysis showed a cumulative incidence of m

211 Kaplan-Meier analysis showed a lower risk for incident N

212 Kaplan-Meier analysis showed a mean time of recurrence o

213 Kaplan-Meier analysis showed a significantly lower event

214 Kaplan-Meier analysis showed clear stratification of hig

215 Twelve months after PIER, Kaplan-Meier analysis showed limb salvage rate was 66%,

216 Kaplan-Meier analysis showed no differences in the incid

217 Kaplan-Meier analysis showed statistically significant d

218 Kaplan-Meier analysis showed survival was 78% at 5 years

219 After 5 years, Kaplan-Meier analysis showed sustained complete remissio

220 Kaplan-Meier analysis showed that dysplasia remained era

221 Kaplan-Meier analysis showed that if a high-quality phot

222 In brain cancer patients, Kaplan-Meier analysis showed that image-derived referenc

223 Kaplan-Meier analysis showed that levels of interleukin-

224 Kaplan-Meier analysis showed that one- and two-year graf

225 Kaplan-Meier analysis showed that patients with GDS>0.86

226 In ER positive cases, Kaplan-Meier analysis showed that patients with lower mi

227 Kaplan-Meier analysis showed that the 1-, 5-, and 10-yea

228 Kaplan-Meier analysis showed that the 50% of the fellow

229 Kaplan-Meier analysis showed that the complete success r

230 A Kaplan-Meier analysis showed that the probability of dev

231 Kaplan-Meier analysis showed that the vaccine group was

232 Kaplan-Meier analysis showed worse survival for patients

233 The Kaplan-Meier analysis shows a trend toward greater freed

234 Kaplan-Meier analysis suggested that neuromonitoring was

235 Kaplan-Meier analysis suggests there is at least an addi

236 On Kaplan-Meier analysis, the median survival in the entire

237 With Kaplan-Meier analysis, the risk of death increased signi

238 On Kaplan-Meier analysis there were no differences in short

239 By Kaplan-Meier analysis, there was no difference in freedo

240 Using unadjusted and adjusted Cox models and Kaplan-Meier analysis, there was no significant differen

241 In Kaplan-Meier analysis, there was significant variability

242 We used Kaplan-Meier analysis to assess disease-specific surviva

243 learance kinetics, measured every 6 h, and a Kaplan-Meier analysis to compare parasite clearance kine

244 those with missing CSRS predictors, we used Kaplan-Meier analysis to describe the time to serious ar

245 Inverse probability weighting was used with Kaplan-Meier analysis to determine amputation-free survi

246 We used Kaplan-Meier analysis to estimate survival rates and Cox

247 We used Kaplan-Meier analysis to evaluate the number of cases of

248 We also conducted Kaplan-Meier analysis to include currently unaffected mu

249 The associations were further delineated by Kaplan-Meier analysis using publicly available mRNA expr

250 By Kaplan-Meier analysis, VA less than 20/200 at 3 years wa

251 The 5-year graft survival by Kaplan Meier analysis was better in SA group than in MA

252 Estimated mean survival time in the Kaplan-Meier analysis was 147 months (95% confidence int

253 Median renal survival from diagnosis by Kaplan-Meier analysis was 5.4 years, and median estimate

254 The estimated cumulative CO rates using Kaplan-Meier analysis was 68%.

255 Five-year disease-free survival on Kaplan-Meier analysis was 82%, and 5-year overall surviv

256 Survival by Kaplan-Meier analysis was 94% (SE 0.01), 91% (0.02), and

257 Median overall survival by Kaplan-Meier analysis was compared between groups using

258 uity, 5-year treatment-success calculated by Kaplan-Meier analysis was only 38.4%.

259 Kaplan-Meier analysis was performed for PTLD-free surviv

260 Kaplan-Meier analysis was performed for time to developm

261 Kaplan-Meier analysis was performed to calculate progres

262 Kaplan-Meier analysis was performed to compare time to e

263 Kaplan-Meier analysis was performed to determine the rel

264 Kaplan-Meier analysis was performed to determine the tim

265 Kaplan-Meier analysis was performed to estimate the cumu

266 A Kaplan-Meier analysis was performed to estimate time to

267 Kaplan-Meier analysis was performed to evaluate graft su

268 Kaplan-Meier analysis was performed to obtain the progre

269 tory abilities of inflammation-based scores; Kaplan-Meier analysis was performed to plot the survival

270 Kaplan-Meier analysis was performed using Criteria A (po

271 Gene-expression based Kaplan-Meier analysis was performed using The Cancer Gen

272 Descriptive statistics and Kaplan-Meier analysis was performed.

273 as in patients with limited life expectancy, Kaplan-Meier analysis was repeated including only patien

274 Kaplan-Meier analysis was then performed on overall graf

275 Kaplan-Meier analysis was used to assess freedom from ne

276 mplications and of need for reoperation, and Kaplan-Meier analysis was used to assess graft survival

277 Kaplan-Meier analysis was used to assess ocular outcome

278 Kaplan-Meier analysis was used to assess the time betwee

279 Kaplan-Meier analysis was used to compare graft and pati

280 Kaplan-Meier analysis was used to determine median time

281 Kaplan-Meier analysis was used to estimate freedom from

282 Kaplan-Meier analysis was used to estimate the cumulativ

283 Kaplan-Meier analysis was used to estimate the time to d

284 Kaplan-Meier analysis was used to examine rates of recip

285 Kaplan-Meier analysis was used to further explore the as

286 Kaplan-Meier analysis was used to obtain survival rates.

287 At 1 year, the rate of death from any cause (Kaplan-Meier analysis) was 30.7% with TAVI, as compared

288 l success at the last follow-up according to Kaplan-Meier analysis were 100% and 94.4% in bevacizumab

289 Univariate, multivariate, and Kaplan-Meier analysis were used as appropriate.

290 Cox multivariable regression and Kaplan-Meier analysis were used to identify factors asso

291 [CI], 0.71 to 1.15; P=0.41) and at 2 years (Kaplan-Meier analysis) were 33.9% in the TAVR group and

292 he 1-, 12-, and 24-month mortality rates (by Kaplan-Meier analysis) were 4.5%, 15.8%, and 15.8%, resp

293 CD20+ cells/hpf had worse graft survival in Kaplan-Meier analysis with a hazard ratio 4.56 (CI 1.07-

294 Kaplan-Meier analysis with log-rank test was used to det

295 Overall survival (OS) was compared using Kaplan-Meier analysis with log-rank tests and multivaria

296 Overall survival was compared using Kaplan-Meier analysis with log-rank tests, multivariable

297 Kaplan-Meier analysis with log-rank was used to determin

298 Univariate Cox regression and Kaplan-Meier analysis with respect to overall survival (

299 ropensity-matched cohorts and illustrated by Kaplan-Meier analysis with subgroup analysis for intermi

300 With median follow up of 29.1 months, Kaplan-Meier analysis with the log-rank test demonstrate